| Schedule of Operating Financial Results |
The following table provides the operating financial results of our biopharmaceutical cancer therapeutics segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
June 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenue |
|
$ |
37,958 |
|
|
$ |
3,500 |
|
|
$ |
57,753 |
|
|
$ |
3,500 |
|
Less: Significant and other segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product sales |
|
|
1,279 |
|
|
|
— |
|
|
|
2,164 |
|
|
|
— |
|
Research and development expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Revumenib-related costs |
|
|
28,155 |
|
|
|
20,439 |
|
|
|
48,960 |
|
|
|
51,880 |
|
Axatilimab-related costs |
|
|
9,053 |
|
|
|
8,503 |
|
|
|
28,764 |
|
|
|
14,104 |
|
Other R&D programs |
|
|
1,826 |
|
|
|
534 |
|
|
|
2,747 |
|
|
|
1,500 |
|
Personnel cost and other expenses |
|
|
18,997 |
|
|
|
14,861 |
|
|
|
35,528 |
|
|
|
29,202 |
|
General and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Commercial-related expenses |
|
|
9,914 |
|
|
|
7,560 |
|
|
|
20,739 |
|
|
|
13,392 |
|
Personnel cost and other expenses |
|
|
19,307 |
|
|
|
4,153 |
|
|
|
38,389 |
|
|
|
8,258 |
|
Other SG&A expenses |
|
|
4,993 |
|
|
|
11,770 |
|
|
|
9,405 |
|
|
|
20,099 |
|
Stock-based compensation |
|
|
13,787 |
|
|
|
9,896 |
|
|
|
24,167 |
|
|
|
18,795 |
|
Royalty interest expense |
|
|
7,854 |
|
|
|
— |
|
|
|
15,903 |
|
|
|
— |
|
Interest expense (income), net |
|
|
(5,946 |
) |
|
|
(6,239 |
) |
|
|
(13,127 |
) |
|
|
(13,440 |
) |
Other expense, net |
|
|
586 |
|
|
|
86 |
|
|
|
807 |
|
|
|
173 |
|
Segment net loss |
|
$ |
(71,847 |
) |
|
$ |
(68,063 |
) |
|
$ |
(156,693 |
) |
|
$ |
(140,463 |
) |
|